Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles

https://journals.asm.org/doi/10.1128/jvi.00681-24?utm_campaign=+62003350&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= Because there are four types of dengue viruses, each capable of causing human disease via mosquito bites, scientists have struggled to develop one antibody test to accurately recognize each virus. The four virus types also have challenged scientists trying to develop effective dengue vaccines and treatments, none of which exist. Progress could change though, as a recent study published in the Journal of Virology by NIAID scientists explains. The group describes improvements made to a single test (TetraPlex RVPNT) that provides simultaneous measures of infection-related antibody responses against all four virus types from a single clinical sample. The researchers say the advance could eliminate the current need for cumbersome repeated testing for each virus type. Further, they say, the improvements make the test favorable to use in dengue epidemiology and vaccine studies to quickly evaluate antibody responses. They refer to the test as “a transformative tool.”